Shinichi Hasako

MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel

Toshiyasu Shimomura, Shinichi Hasako, Yoko Nakatsuru et al. · Molecular Cancer Therapeutics · 2010 · 118 citations · Full text

TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations

Shinichi Hasako, Miki Terasaka, Naomi Abe et al. · Molecular Cancer Therapeutics · 2018 · 82 citations

TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant <i>EGFR</i> Mutations

Hibiki Udagawa, Shinichi Hasako, Akihiro Ohashi et al. · Molecular Cancer Research · 2019 · 70 citations · Full text

Biological characterization of 2-aminothiazole-derived Cdk4/6 selective inhibitor in vitro and in vivo

Hiroshi Hirai, Toshiyasu Shimomura, Makiko Kobayashi et al. · Cell Cycle · 2010 · 29 citations · Full text

Chemoprevention Strategy, Immunology, Pharmacotherapy +18

Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo

Hiroshi Hirai, Ikuko Takahashi-Suziki, Toshiyasu Shimomura et al. · Investigational New Drugs · 2010 · 18 citations

Medicinal Chemistry, Oncology, Potent Anti-tumor Activity +7